Management
Robert M. Brenner, M.D., President and Chief Executive Officer
Robert M. Brenner, M.D. joined AlloCure in 2010 from AMAG Pharmaceuticals, where he was Senior Vice President of Medical Affairs and responsible for the company's nephrology clinical development activities. Previously, Dr. Brenner was at Amgen for nine years where he served in a variety of nephrology leadership roles both in clinical development and medical affairs, ultimately holding the title of Executive Director and Renal Anemia Global Program Area Leader. During his career, Dr. Brenner contributed to the approval of new products, led the design of clinical trials, and was a key liaison to the nephrology community, professional societies and regulatory agencies. Dr. Brenner received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency in internal medicine at Brigham and Women's Hospital in Boston and his fellowship in nephrology at Stanford University Medical Center.
Robert M. Brenner, M.D. joined AlloCure in 2010 from AMAG Pharmaceuticals, where he was Senior Vice President of Medical Affairs and responsible for the company's nephrology clinical development activities. Previously, Dr. Brenner was at Amgen for nine years where he served in a variety of nephrology leadership roles both in clinical development and medical affairs, ultimately holding the title of Executive Director and Renal Anemia Global Program Area Leader. During his career, Dr. Brenner contributed to the approval of new products, led the design of clinical trials, and was a key liaison to the nephrology community, professional societies and regulatory agencies. Dr. Brenner received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency in internal medicine at Brigham and Women's Hospital in Boston and his fellowship in nephrology at Stanford University Medical Center.
George Eldridge - Chief Financial Officer
George Eldridge joined AlloCure in 2010 as part-time Chief Financial Officer. Previously, he was Chief Financial Officer for Targanta Therapeutics, a company in the antibiotics field that Mr. Eldridge helped raise $70 million in venture funding, took public in 2007, and then sold in 2009 to The Medicines Company. Before Targanta, Mr. Eldridge worked as Chief Financial Officer for Therion Biologics, Curis (previously Ontogeny), and Boston Life Sciences. Mr. Eldridge orchestrated reverse merger transactions to take Ontogeny and Boston Life Sciences public and subsequently completed follow-on financings for each of these companies. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. and received an M.B.A. from the University of Chicago and a B.A. in Government and Economics from Dartmouth College.
George Eldridge joined AlloCure in 2010 as part-time Chief Financial Officer. Previously, he was Chief Financial Officer for Targanta Therapeutics, a company in the antibiotics field that Mr. Eldridge helped raise $70 million in venture funding, took public in 2007, and then sold in 2009 to The Medicines Company. Before Targanta, Mr. Eldridge worked as Chief Financial Officer for Therion Biologics, Curis (previously Ontogeny), and Boston Life Sciences. Mr. Eldridge orchestrated reverse merger transactions to take Ontogeny and Boston Life Sciences public and subsequently completed follow-on financings for each of these companies. Prior to working in the biotechnology field, Mr. Eldridge was an investment banker at Kidder Peabody & Co. and received an M.B.A. from the University of Chicago and a B.A. in Government and Economics from Dartmouth College.
Kevin J. Heyeck - Chief Business Officer
Kevin Heyeck joined AlloCure in 2011 as Chief Business Officer. Prior to joining AlloCure, Mr. Heyeck was Vice President, Business Development at Vitae Pharmaceuticals, where he headed Vitae's business development activities and was responsible for securing multiple major partnerships, generating $100M in non-contingent capital. Prior to Vitae, Mr. Heyeck headed Business Development for Pharmacopeia, a company that was a pioneer in the use of combinatorial chemistry in drug discovery. While there he was responsible for over twenty partnerships with large pharmaceutical and biotechnology companies worldwide. Prior to Pharmacopeia, Mr. Heyeck was Technology Transfer Officer at Harvard University. He received his B.A. at the University of California, Santa Cruz.
Kevin Heyeck joined AlloCure in 2011 as Chief Business Officer. Prior to joining AlloCure, Mr. Heyeck was Vice President, Business Development at Vitae Pharmaceuticals, where he headed Vitae's business development activities and was responsible for securing multiple major partnerships, generating $100M in non-contingent capital. Prior to Vitae, Mr. Heyeck headed Business Development for Pharmacopeia, a company that was a pioneer in the use of combinatorial chemistry in drug discovery. While there he was responsible for over twenty partnerships with large pharmaceutical and biotechnology companies worldwide. Prior to Pharmacopeia, Mr. Heyeck was Technology Transfer Officer at Harvard University. He received his B.A. at the University of California, Santa Cruz.
Dena M. Minning, M.D., Ph.D. - Vice President, Translational Research
Dena Minning, M.D., Ph.D., joined AlloCure in 2011 as Vice President of Translational Research. Previously, Dr. Minning served as Vice President of Translational Medicine at 3-V Biosciences, overseeing preclinical and clinical activities. Prior to 3-V, Dr. Minning was a Director in Early Development at Amgen, where she led therapeutic programs in anemia, heart failure, myelodysplastic syndromes, and pain, and developed additional drug candidates for asthma and dyslipidemia. Earlier at Amgen, Dr. Minning was an Associate Director in Licensing, where she played a significant leadership role in the successful partnership with Cytokinetics. Dr. Minning received her B.S. from the University of Florida and her M.D. and Ph.D. from Washington University in St. Louis. Her post-graduate internal medicine training was performed at University of California, San Francisco.
Dena Minning, M.D., Ph.D., joined AlloCure in 2011 as Vice President of Translational Research. Previously, Dr. Minning served as Vice President of Translational Medicine at 3-V Biosciences, overseeing preclinical and clinical activities. Prior to 3-V, Dr. Minning was a Director in Early Development at Amgen, where she led therapeutic programs in anemia, heart failure, myelodysplastic syndromes, and pain, and developed additional drug candidates for asthma and dyslipidemia. Earlier at Amgen, Dr. Minning was an Associate Director in Licensing, where she played a significant leadership role in the successful partnership with Cytokinetics. Dr. Minning received her B.S. from the University of Florida and her M.D. and Ph.D. from Washington University in St. Louis. Her post-graduate internal medicine training was performed at University of California, San Francisco.
Viken Paragamian, BSc, Vice President, Clinical Development
Viken Paragamian joined AlloCure in 2010. Most recently, Mr. Paragamian served as President of Paracore Solutions, where he provided senior-level Clinical Development and Regulatory consultation to the biopharmaceutical industry, specializing in the fields of Nephrology, Gene and Cell Therapies, and Oncology. Previously, Mr. Paragamian was at Amgen Canada Inc. for 15 years, where he served in a variety of positions across the organization, ultimately holding the title of Vice President, Scientific Affairs and Chief Scientific Officer. In his role, Mr. Paragamian oversaw the Clinical Operations, Regulatory Affairs, and Medical Affairs functions. He led the design and implementation of clinical trials and liaised with regulatory agencies as well as thought leaders in the areas of Nephrology, Oncology, and Rheumatology. Mr. Paragamian is a graduate of McGill University.
Viken Paragamian joined AlloCure in 2010. Most recently, Mr. Paragamian served as President of Paracore Solutions, where he provided senior-level Clinical Development and Regulatory consultation to the biopharmaceutical industry, specializing in the fields of Nephrology, Gene and Cell Therapies, and Oncology. Previously, Mr. Paragamian was at Amgen Canada Inc. for 15 years, where he served in a variety of positions across the organization, ultimately holding the title of Vice President, Scientific Affairs and Chief Scientific Officer. In his role, Mr. Paragamian oversaw the Clinical Operations, Regulatory Affairs, and Medical Affairs functions. He led the design and implementation of clinical trials and liaised with regulatory agencies as well as thought leaders in the areas of Nephrology, Oncology, and Rheumatology. Mr. Paragamian is a graduate of McGill University.
John B. Wirthlin, MBA, Chief Operating Officer
John B. Wirthlin joined AlloCure as founding CEO in 2006. Since joining the company, he played a major role in the successful IND filing and execution of the Phase 1 clinical trial targeting acute renal failure. In June of 2008 Mr. Wirthlin led AlloCure through the closing of a Series A financing with SV Life Sciences and Novo A/S. Mr. Wirthlin previously worked for Echelon Biosciences where he served as Secretary of the Board, Director of Business Development and Director of Operations. Echelon was acquired by Aeterna Zentaris in 2004. Prior to joining Echelon, he worked in the financial services and investment banking sector. Mr. Wirthlin received his MBA from Westminster College with an emphasis on technology commercialization.
John B. Wirthlin joined AlloCure as founding CEO in 2006. Since joining the company, he played a major role in the successful IND filing and execution of the Phase 1 clinical trial targeting acute renal failure. In June of 2008 Mr. Wirthlin led AlloCure through the closing of a Series A financing with SV Life Sciences and Novo A/S. Mr. Wirthlin previously worked for Echelon Biosciences where he served as Secretary of the Board, Director of Business Development and Director of Operations. Echelon was acquired by Aeterna Zentaris in 2004. Prior to joining Echelon, he worked in the financial services and investment banking sector. Mr. Wirthlin received his MBA from Westminster College with an emphasis on technology commercialization.
Board of Directors
Mette Kirstine Agger, Lundbeckfond Ventures
Mette Kirstine Agger is Managing Partner of Lundbeckfond Ventures and has over 20 years of broad international leadership experience within biotech / life science covering business development and licensing, management and financing. Mette was previously co-founder and CEO of 7TM Pharma A/S. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has served on numerous boards both in private and public companies. Her current board memberships include DBV Technologies and Veloxis. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.
Mette Kirstine Agger is Managing Partner of Lundbeckfond Ventures and has over 20 years of broad international leadership experience within biotech / life science covering business development and licensing, management and financing. Mette was previously co-founder and CEO of 7TM Pharma A/S. Prior to founding 7TM Pharma, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has served on numerous boards both in private and public companies. Her current board memberships include DBV Technologies and Veloxis. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.
Robert M. Brenner, M.D., President and Chief Executive Officer
Robert M. Brenner, M.D. joined AlloCure in 2010 from AMAG Pharmaceuticals, where he was Senior Vice President of Medical Affairs and responsible for the company's nephrology clinical development activities. Previously, Dr. Brenner was at Amgen for nine years where he served in a variety of nephrology leadership roles both in clinical development and medical affairs, ultimately holding the title of Executive Director and Renal Anemia Global Program Area Leader. During his career, Dr. Brenner contributed to the approval of new products, led the design of clinical trials, and was a key liaison to the nephrology community, professional societies and regulatory agencies. Dr. Brenner received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency in internal medicine at Brigham and Women's Hospital in Boston and his fellowship in nephrology at Stanford University Medical Center.
Robert M. Brenner, M.D. joined AlloCure in 2010 from AMAG Pharmaceuticals, where he was Senior Vice President of Medical Affairs and responsible for the company's nephrology clinical development activities. Previously, Dr. Brenner was at Amgen for nine years where he served in a variety of nephrology leadership roles both in clinical development and medical affairs, ultimately holding the title of Executive Director and Renal Anemia Global Program Area Leader. During his career, Dr. Brenner contributed to the approval of new products, led the design of clinical trials, and was a key liaison to the nephrology community, professional societies and regulatory agencies. Dr. Brenner received his B.A. from Johns Hopkins University and his M.D. from Albert Einstein College of Medicine. He completed his medical residency in internal medicine at Brigham and Women's Hospital in Boston and his fellowship in nephrology at Stanford University Medical Center.
Thomas Dyrberg, M.D., Novo Ventures, Novo A/S
Thomas Dyrberg joined Novo A/S in 2000. He is a member of the boards of directors of AlloCure Inc., LifeCycle Pharma A/S, Lux Biosciences Inc. and Ophthotech Corporation, and was a board member of BioMimetic Therapeutics, Inc., Gloucester Pharmaceuticals, HemoFocus ApS and Sapphire Therapeutics, Inc. Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development as an International Clinical Project Manager. Thomas obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.
Thomas Dyrberg joined Novo A/S in 2000. He is a member of the boards of directors of AlloCure Inc., LifeCycle Pharma A/S, Lux Biosciences Inc. and Ophthotech Corporation, and was a board member of BioMimetic Therapeutics, Inc., Gloucester Pharmaceuticals, HemoFocus ApS and Sapphire Therapeutics, Inc. Thomas held research positions at the Hagedorn Research Institute, Denmark, and at the Scripps Research Institute, La Jolla, USA. In 1990, he joined Novo Nordisk A/S, initially working in Health Care Discovery on various aspects of diabetes immunology and pathogenesis, and from 1996 in Health Care Clinical Drug Development as an International Clinical Project Manager. Thomas obtained an MD degree from the University of Copenhagen in 1981 and a DMSc degree, also from the University of Copenhagen in 1986.
Lutz Giebel, Ph.D., SV Life Sciences
Dr. Lutz Giebel is a Managing Partner based in San Francisco. Lutz currently serves the boards of Alba, AlloCure, Avera, Logical Therapeutics, Lux Biosciences, Neurotech, and Panoptica. Before joining SV Life Sciences in 2001 he was a Managing Partner of Didyma LLC, a biotechnology management consulting firm. Lutz was Founder, President and CEO of CyThera Inc., Founder and Chief Operating Officer of ExSAR and was Founder and Vice President of Research of MetaXen, LLC, now part of Exelixis. He joined Arris Pharmaceutical, now part of Celera, as the first biologist and subsequently held various management positions, including Senior Director of Molecular Biology. Lutz received his Ph.D. in Molecular Biology at the University of Heidelberg, Germany and did his Post Doctoral studies in Human Genetics at the University of Wisconsin, Madison.
Dr. Lutz Giebel is a Managing Partner based in San Francisco. Lutz currently serves the boards of Alba, AlloCure, Avera, Logical Therapeutics, Lux Biosciences, Neurotech, and Panoptica. Before joining SV Life Sciences in 2001 he was a Managing Partner of Didyma LLC, a biotechnology management consulting firm. Lutz was Founder, President and CEO of CyThera Inc., Founder and Chief Operating Officer of ExSAR and was Founder and Vice President of Research of MetaXen, LLC, now part of Exelixis. He joined Arris Pharmaceutical, now part of Celera, as the first biologist and subsequently held various management positions, including Senior Director of Molecular Biology. Lutz received his Ph.D. in Molecular Biology at the University of Heidelberg, Germany and did his Post Doctoral studies in Human Genetics at the University of Wisconsin, Madison.
© 2012 AlloCure
